

contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5% cross-linking agent substantially free from polyalkenyl polyether, said percentages being based upon the weights of unpolymerised repeating unit and cross-linking agent, respectively, with (2) water, in the presence of an SSRI.

23. The process of claim 22 in which the SSRI is paroxetine, fluoxetine, fluvoxamine or sertraline, or a pharmaceutically acceptable salt thereof.

24. The process of claim 23 in which the SSRI is paroxetine or a pharmaceutically acceptable salt thereof.

REMARKS

Applicants respectfully request examination of the instant application as amended herein. The instant amendments are made to eliminate multiple dependent claims and put the application in better form for examination.

If any matters remain to be resolved before search, examination and allowance, or discussion of any matter will facilitate the prosecution of this application, the Examiner is invited to call the undersigned attorney at the number provided.

Respectfully submitted,



Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090

- 5 -

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Applicants note that all of the previously pending claims have been deleted and replaced by a new claim set. As such, a marked-up version of the claims is not necessary.

[illegible]